|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ronald Aung-Din, MD, and Chantelle Martin, MBChB, explain how targeting such chronic pain with a fast-acting, non-systemic, convenient, and easy-to-use at-home NeuroDirect ketamine cream could be of significant benefit in patients with CRPS as well as other neuropathic pain states, including chronic neck and back pain.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, shed light on the design and formation of cubosomes with special focus on their applications for delivery of hydrophobic and hydrophilic small and large molecules, including oncology drugs and polynucleotides (DNA, mRNA, and siRNA).
|
|
|
Tony Listro, Vice President of Technology and Site Lead for SPS’s North American site in Putnam, CT, discusses the company’s recent focus areas as well as current plans for expansion.
|
|
|
Charlotte Dunne, PhD, Katrin Radloff, PhD, and Leonidas Gkionis, PhD, review the PTXΔLNP platform and how it offers a synergistic sister technology to the mRNA platform to obtain potent mRNA-LNPs for therapeutic applications.
|
|
|
|
|
|
|
|
|

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.
|
|
|
|
|
|
 |
|
The outlook for pharma services in 2024 is continuing to improve, with 94% of the industry either “moderately positive” (37%) or “highly positive” (37%) on growth for contract packaging in….
|
|
 |
|
Partners STADA and Alvotech recently announced the European Commission issued a marketing authorization for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab). The centralized marketing….
|
|
 |
|
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWire (NNW), one of 60+ brands within the….
|
|
 |
|
Widely recognized as a pioneer in continuous manufacturing, Pune-based Contract Development & Manufacturing Organization (CDMO), Enzene Biosciences has announced the launch of its first manufacturing site in the US, located in….
|
|
|
|
|
|
|
|
 |
|
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
|
|
 |
|
Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….
|
|
 |
|
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
|
|
|
|
|
|
|
|
 |
|
By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks …
|
|
 |
|
Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.
Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared …
|
|
 |
|
By: Dr. Bahar Yeniad and Dr. Pieter van Delft
Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …
|
|
|
|
|
Upcoming eNewsletter Features:
January 24 – Bioavailability
January 31 – Analytical Testing
|
|
|
|
|
|
|
|